{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:15:11Z","timestamp":1788275711930,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03733-x","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:45:37Z","timestamp":1788273937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administered with a Prefilled Syringe"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct05817435","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Cassandra","family":"De Muynck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Noukens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Allosery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Cettour-Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9gol\u00e8ne","family":"Pastouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Borgions","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"issue":"4","key":"3733_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","volume":"278","author":"L Wang","year":"2015","unstructured":"Wang L, Wang F-S, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369\u201395.","journal-title":"J Intern Med"},{"key":"3733_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","volume":"8","author":"RJ Ludwig","year":"2017","unstructured":"Ludwig RJ, Vanhoorelbeke K, Leypoldt F, et al. Mechanisms of autoantibody-induced pathology. Front Immunol. 2017;8:603.","journal-title":"Front Immunol"},{"issue":"6","key":"3733_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103326","volume":"22","author":"F Cao","year":"1990","unstructured":"Cao F, He YS, Wang Y, et al. Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019. Autoimmun Rev. 1990;22(6):103326.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"3733_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/WNO.0000000000000132","volume":"34","author":"SJ Shan","year":"2014","unstructured":"Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177\u201385.","journal-title":"J Neuroophthalmol"},{"issue":"5","key":"3733_CR5","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jaci.2022.05.023","volume":"150","author":"M Volkov","year":"2022","unstructured":"Volkov M, Coppola M, Huizinga R, et al. Comprehensive overview of autoantibody isotype and subclass distribution. J Allergy Clin Immunol. 2022;150(5):999\u20131010.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3733_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/nyas.13561","volume":"1413","author":"MG Huijbers","year":"2018","unstructured":"Huijbers MG, Plomp JJ, van der Maarel SM, Verschuuren JJ. IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders. Ann N Y Acad Sci. 2018;1413(1):92\u2013103.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"3733_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","volume":"146","author":"DD Patel","year":"2020","unstructured":"Patel DD, Bussel JB. Neonatal Fc receptor in human immunity: function and role in therapeutic intervention. J Allergy Clin Immunol. 2020;146(3):467\u201378.","journal-title":"J Allergy Clin Immunol"},{"issue":"15","key":"3733_CR8","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1007\/s00018-010-0318-6","volume":"67","author":"A Sesarman","year":"2010","unstructured":"Sesarman A, Vidarsson G, Sitaru C. The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases. Cell Mol Life Sci. 2010;67(15):2533\u201350.","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"3733_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102366","volume":"18","author":"AW Zuercher","year":"2019","unstructured":"Zuercher AW, Spirig R, Baz Morelli A, Rowe T, Kasermann F. Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev. 2019;18(10):102366.","journal-title":"Autoimmun Rev"},{"key":"3733_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.673339","volume":"12","author":"E Sechi","year":"2021","unstructured":"Sechi E, Flanagan EP. Antibody-mediated autoimmune diseases of the CNS: challenges and approaches to diagnosis and management. Front Neurol. 2021;12:673339.","journal-title":"Front Neurol"},{"issue":"2","key":"3733_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","volume":"20","author":"R Iorio","year":"2024","unstructured":"Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol. 2024;20(2):84\u201398.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"3733_CR12","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372\u201386.","journal-title":"J Clin Invest"},{"issue":"10","key":"3733_CR13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","volume":"39","author":"ES Ward","year":"2018","unstructured":"Ward ES, Ober RJ. Targeting FcRn to generate antibody-based therapeutics. Trends Pharmacol Sci. 2018;39(10):892\u2013904.","journal-title":"Trends Pharmacol Sci"},{"key":"3733_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.","journal-title":"Front Immunol"},{"key":"3733_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fimmu.2015.00176","volume":"6","author":"AE Nixon","year":"2015","unstructured":"Nixon AE, Chen J, Sexton DJ, et al. Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates. Front Immunol. 2015;6:176.","journal-title":"Front Immunol"},{"key":"3733_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.892534","volume":"13","author":"ES Ward","year":"2022","unstructured":"Ward ES, Gelinas D, Dreesen E, et al. Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders. Front Immunol. 2022;13:892534.","journal-title":"Front Immunol"},{"issue":"1","key":"3733_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/1547691X.2025.2459934","volume":"22","author":"O Binazon","year":"2025","unstructured":"Binazon O, Cocco M, Thwaites D, et al. Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys. J Immunotoxicol. 2025;22(1):2459934.","journal-title":"J Immunotoxicol"},{"issue":"7","key":"3733_CR18","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"issue":"8","key":"3733_CR19","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/08916934.2022.2104261","volume":"55","author":"JT Guptill","year":"2022","unstructured":"Guptill JT, Sleasman JW, Steeland S, et al. Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis. Autoimmunity. 2022;55(8):620\u201331.","journal-title":"Autoimmunity"},{"key":"3733_CR20","unstructured":"VYVGART. Summary of product characteristics. argenx; 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyvgart-epar-product-information_en.pdf"},{"key":"3733_CR21","unstructured":"VYVGART HYTRULO. Prescribing information. argenx. 2025. https:\/\/argenx.com\/content\/dam\/argenx-corp\/products\/vyvgart-hytrulo-prescribing-information.pdf.coredownload.inline.pdf."},{"issue":"5","key":"3733_CR22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40263-023-01000-z","volume":"37","author":"YA Heo","year":"2023","unstructured":"Heo YA. Efgartigimod alfa in generalised myasthenia gravis: a profile of its use. CNS Drugs. 2023;37(5):467\u201373.","journal-title":"CNS Drugs"},{"issue":"5","key":"3733_CR23","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/1744666X.2025.2497840","volume":"21","author":"KG Gwathmey","year":"2025","unstructured":"Gwathmey KG, Broome CM, Goebeler M, et al. Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases. Expert Rev Clin Immunol. 2025;21(5):627\u201338.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"3733_CR24","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/ajh.27448","volume":"99","author":"H Al-Samkari","year":"2025","unstructured":"Al-Samkari H. 2025 update on clinical trials in immune thrombocytopenia. Am J Hematol. 2025;99(11):2178\u201390.","journal-title":"Am J Hematol"},{"issue":"3","key":"3733_CR25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA. Efgartigimod: first approval. Drugs. 2022;82(3):341\u20138.","journal-title":"Drugs"},{"issue":"5","key":"3733_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00378","volume":"21","author":"JF Howard Jr.","year":"2024","unstructured":"Howard JF Jr., Vu T, Li G, et al. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+). Neurotherapeutics. 2024;21(5):e00378.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"3733_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","volume":"26","author":"KW Locke","year":"2019","unstructured":"Locke KW, Maneval DC, LaBarre MJ. ENHANZE((R)) drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv. 2019;26(1):98\u2013106.","journal-title":"Drug Deliv"},{"key":"3733_CR28","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/PPA.S303279","volume":"15","author":"PM Overton","year":"2021","unstructured":"Overton PM, Shalet N, Somers F, Allen JA. Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adher. 2021;15:811\u201334.","journal-title":"Patient Prefer Adher"},{"issue":"12","key":"3733_CR29","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/17425247.2018.1546692","volume":"15","author":"AR Kafal","year":"2018","unstructured":"Kafal AR, Vinh DC, Langelier MJ. Prefilled syringes for immunoglobulin G (IgG) replacement therapy: clinical experience from other disease settings. Expert Opin Drug Deliv. 2018;15(12):1199\u2013209.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"3733_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s41120-022-00069-y","volume":"9","author":"B Bittner","year":"2023","unstructured":"Bittner B. Customer-centric product presentations for monoclonal antibodies. AAPS Open. 2023;9(1):3.","journal-title":"AAPS Open"},{"issue":"4","key":"3733_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4103\/2230-973X.93004","volume":"1","author":"S Makwana","year":"2011","unstructured":"Makwana S, Basu B, Makasana Y, Dharamsi A. Prefilled syringes: an innovation in parenteral packaging. Int J Pharm Investig. 2011;1(4):200\u20136.","journal-title":"Int J Pharm Investig"},{"key":"3733_CR32","unstructured":"Preparing a manuscript for submission to a medical journal. International Committee of Medical Journal Editors (ICMJE) website. 2026. https:\/\/www.icmje.org\/recommendations\/browse\/manuscript-preparation\/preparing-for-submission.html Accessed 08 July 2026."},{"issue":"12","key":"3733_CR33","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2217\/imt-2017-0092","volume":"9","author":"RL Wasserman","year":"2017","unstructured":"Wasserman RL. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. Immunotherapy (Lond). 2017;9(12):1035\u201350.","journal-title":"Immunotherapy (Lond)"},{"issue":"2","key":"3733_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jconrel.2006.05.027","volume":"114","author":"LH Bookbinder","year":"2006","unstructured":"Bookbinder LH, Hofer A, Haller MF, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release. 2006;114(2):230\u201341.","journal-title":"J Control Release"},{"key":"3733_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2147\/PPA.S60771","volume":"8","author":"T Espanol","year":"2014","unstructured":"Espanol T, Prevot J, Drabwell J, Sondhi S, Olding L. Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment. Patient Prefer Adherence. 2014;8:621\u20139.","journal-title":"Patient Prefer Adherence"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03733-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03733-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03733-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:45:39Z","timestamp":1788273939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03733-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":35,"alternative-id":["3733"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03733-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jan Noukens acted as a consultant paid by argenx. Anthony D. Andre is an employee of and shareholder in Interface Analysis Associates LLC. Cassandra De Muynck, Filip Borgions, Koen Allosery, Clotilde Cettour-Rose, and S\u00e9gol\u00e8ne Pastouret are employees of argenx.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The bioequivalence study and the injection speed study were conducted in accordance with consensus ethical principles derived from international guidelines, including the Declaration of Helsinki 1964 and its later amendments and the Council for International Organizations of Medical Sciences international ethical guidelines, applicable ICH Good Clinical Practice guidelines, and local laws and regulations. IRB approval for the bioequivalence study was granted by Advarra (Columbia, MS, US; approval no. Pro00074818, October 10, 2023). IRB approval for the injection speed study was granted by Advarra (Columbia, MD, USA; approval no. Pro00072919). The HF studies were designed in accordance with the US Food and Drug Administration Application of Human Factors Engineering Principles for Combination Products: Questions and Answers; Contents of a Complete Submission for Threshold Analyses and Human Factors Submissions to Drug and Biologic Applications; and Human Factors Studies and Related Clinical Study Considerations in Combination Product Design and Development guidelines. All participants provided informed consent before participation. All study documents, including the recruiting screener, informed consent form, and any other requested documents, were reviewed and approved by Salus IRB (Austin, TX, USA; approval nos IAA-2342 and IAA-2401, December 11, 2023, and December 14, 2023, respectively) before conducting these studies.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}